Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement
News|Slideshows|August 29, 2025

August Pharmaceutical Industry Movers & Shakers

Author(s)Don Tracy, Associate Editor

A monthly roundup of business and people news in the pharmaceutical industry.

Advertisement

Advertisement
Corporate Communications

Related Content

Advertisement
stock.adobe.com drug pricing

Trump Administration Adds Nine Drugmakers to Most-Favored-Nation Program: Report

ByNicholas Jacobus
August 31st 2026
Pharmaceutical Executive Daily

Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences

ByNicholas Jacobus
August 31st 2026
stock.adobe.com acquire

Eli Lilly to Acquire Merida Biosciences for $2.8 Billion

ByNicholas Jacobus
August 31st 2026
Stock.Adobe.com Clinical trial

BioNTech Terminates Phase II Clinical Trial for Cevumeran

ByNicholas Jacobus
August 31st 2026
Parth Khanna

The Future Relationship Between AI and Field Reps

ByMike Hollan,Parth Khanna
August 31st 2026
Advertisement
Advertisement

Trending on PharmExec

1

Trump Administration Adds Nine Drugmakers to Most-Favored-Nation Program: Report

2

Eli Lilly to Acquire Merida Biosciences for $2.8 Billion

3

The Future Relationship Between AI and Field Reps

4

BioNTech Terminates Phase II Clinical Trial for Cevumeran

5

Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us